                         SEQUENCE LISTING

<110>  BRISTOL-MYERS SQUIBB COMPANY
       QIAO, JENNIFER X.
       POSS, MICHAEL A.
       ZHANG, YUNHUI
       ALLEN, MARTIN PATRICK
 
<120>  IMMUNOMODULATORS

<130>  3338.281PC01

<150>  US 63/165,455
<151>  2021-03-24

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  384
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Recombinant Human PD-1-Ig -- hPD1(25-167)-3S-IG

<400>  1

Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr Phe Ser Pro Ala 
1               5                   10                  15      


Leu Leu Val Val Thr Glu Gly Asp Asn Ala Thr Phe Thr Cys Ser Phe 
            20                  25                  30          


Ser Asn Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr Arg Met Ser Pro 
        35                  40                  45              


Ser Asn Gln Thr Asp Lys Leu Ala Ala Phe Pro Glu Asp Arg Ser Gln 
    50                  55                  60                  


Pro Gly Gln Asp Cys Arg Phe Arg Val Thr Gln Leu Pro Asn Gly Arg 
65                  70                  75                  80  


Asp Phe His Met Ser Val Val Arg Ala Arg Arg Asn Asp Ser Gly Thr 
                85                  90                  95      


Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro Lys Ala Gln Ile Lys Glu 
            100                 105                 110         


Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg Ala Glu Val Pro 
        115                 120                 125             


Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Gly Gln Phe Gln Gly 
    130                 135                 140                 


Ser Pro Gly Gly Gly Gly Gly Arg Glu Pro Lys Ser Ser Asp Lys Thr 
145                 150                 155                 160 


His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu Gly Gly Ser Ser 
                165                 170                 175     


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 
            180                 185                 190         


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 
        195                 200                 205             


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 
    210                 215                 220                 


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 
225                 230                 235                 240 


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 
                245                 250                 255     


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 
            260                 265                 270         


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 
        275                 280                 285             


Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 
    290                 295                 300                 


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 
305                 310                 315                 320 


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 
                325                 330                 335     


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 
            340                 345                 350         


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 
        355                 360                 365             


Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
    370                 375                 380                 


<210>  2
<211>  237
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Recombinant Human PD-L1-TVMV-His (PD-L1-His) -- 
       hPDL1(19-239)-TVMV-His

<400>  2

Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr Gly Ser 
1               5                   10                  15      


Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu Asp Leu 
            20                  25                  30          


Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile Ile Gln 
        35                  40                  45              


Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser Tyr Arg 
    50                  55                  60                  


Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn Ala Ala 
65                  70                  75                  80  


Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr Arg Cys 
                85                  90                  95      


Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val Lys Val 
            100                 105                 110         


Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val Asp Pro 
        115                 120                 125             


Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr Pro Lys 
    130                 135                 140                 


Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser Gly Lys 
145                 150                 155                 160 


Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn Val Thr 
                165                 170                 175     


Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr Cys Thr 
            180                 185                 190         


Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu Val Ile 
        195                 200                 205             


Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr Gly Ser Ser 
    210                 215                 220                 


Glu Thr Val Arg Phe Gln Gly His His His His His His 
225                 230                 235         


